Tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). Also shown to inhibit the transmembrane receptor kit and platelet-derived growth factor (PDGF) receptors.
Product Details
| Alternative Name: | STI-571, CGP-57148B |
| |
| Formula: | C29H31N7O . CH3SO3H |
| |
| MW: | 493.6 . 96.1 |
| |
| CAS: | 220127-57-1 |
| |
| MI: | 14: 4902 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | White to pale yellow crystalline powder. |
| |
| Solubility: | Soluble in water (200mg/ml) or DMSO (100mg/ml) or DMF (10mg/ml) or PBS (2mg/ml). Sparingly soluble in ethanol (0.2mg/ml). Storing aqueous solutions for more than one day is not recommended. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | +4°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17- prostacyclin signalling axis: A.J. Ainscough, et al.; Commun. Biol.
5, s42003 (2023),
Abstract;
An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis: A.J. Ainscough, et al.; Commun. Biol.
5, 1192 (2022),
Abstract;
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma: I. Berestjuk, et al.; EMBO Mol. Med.
14, e11814 (2022),
Abstract;
Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models: F. Muselli, et al.; Cancers
13, 1693 (2021),
Abstract;
Full Text
Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials: C.J. Korbee, et al.; Nat. Commun.
9, 358 (2018),
Abstract;
Full Text
Direct modification of the 5-HT3 receptor current by some anticancer drugs: Y. Nakamura, et al.; Eur. J. Pharmacol.
821, 21 (2017),
Abstract;
Importance of pulmonary vein preferential fibrosis for atrial fibrillation promotion in hypertensive rat hearts: Y. Iwasaki, et al.; Can. J. Cardiol.
32, 767 (2016),
Application(s): Cell Culture,
Abstract;
Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling: M.T. Weigel, et al.; Cancer Lett.
273, 70 (2009),
Abstract;
Imatinib as a novel therapeutic approach for fibrotic disorders: J.H. Distler & O. Distler; Rheumatology (Oxford)
48, 2 (2009),
Abstract;
Imatinib mesylate for the treatment of chronic myeloid leukemia: S. Soverini, et al.; Expert Rev. Anticancer Ther.
8, 853 (2008), (Review),
Abstract;
Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?: F. Miselli, et al.; Transl. Oncol.
1, 177 (2008),
Abstract;
Imatinib: C.E. de Kogel & J.H. Schellens; Oncologist
12, 1390 (2007), (Review),
Abstract;
The kinase inhibitor imatinib--an immunosuppressive drug?: D. Wolf, et al.; Cancer Drug Targets
7, 251 (2007), (Review),
Abstract;
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors: E. Buchdunger, et al.; J. Pharmacol. Exp. Ther.
295, 139 (2000),
Abstract;
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative: E. Buchdunger, et al.; Cancer Res.
56, 100 (1996),
Abstract;
